![]() |
|
|
|
Essential Fatty Acid Metabolite (Efam) Model of CFS Management Validated by Successful Predictions: Future Directions Martinovic A.M .(MBBS), Gray J.B. (CPEng, FIE Aust) Telephone:
07 3274 2352 Our previous EFAM Hypothesis of CFS pathogenesis allowed for aetiological and pathogenetic heterogeneity predicting beneficial effect of :
Open case series evaluation of adjuvant EFAM modulations showed dramatic short and long term response in long term incapacitated primary care patients Randomized
controlled trials support various individual components of EFAM model
: CBT evaluated in filtered CFS patient populations unrepresentative of general practice CFS populations; hence carte-blanche prescription of unmetered CBT in all CFS sub-populations unsound. However evidence that CFS subsets with higher depression scores show significant improvement with CBT corroborates our call to treat on titrated as needs basis These studies together corroborate our EFAM management model and case series. Voluminous basic science supports EFAM pathogenesis of symptoms, offering common objective framework for various contentious CFS case definitions and likely aetiological heterogeneity If further hypothesis predictions are confirmed, this will further validate this emerging treatment model e.g. :
Future research indicated to refine biological markers for convenient titration of treatments via this EFAM model. Latest News | Research | Information | Advocacy | Conference | Guidelines
|